These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 8578544)

  • 21. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
    Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
    Thromb Res; 2000 Apr; 98(2):175-85. PubMed ID: 10713319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
    Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
    Becker RC; Alexander J; Dyke CK; Harrington RA
    Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
    Nagashima H
    J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
    Chino D; Fujita Y; Ishii K; Nakayama K
    J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibition of Porphyromonas gingivalis growth by a factor Xa inhibitor, DX-9065a.
    Matsushita K; Imamura T; Tancharoen S; Tatsuyama S; Tomikawa M; Travis J; Potempa J; Torii M; Maruyama I
    J Periodontal Res; 2006 Jun; 41(3):171-6. PubMed ID: 16677284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
    Abendschein DR; Baum PK; Martin DJ; Vergona R; Post J; Rumennik G; Sullivan ME; Eisenberg PR; Light DR
    J Cardiovasc Pharmacol; 2000 May; 35(5):796-805. PubMed ID: 10813384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
    Shu E; Matsuno H; Ishisaki A; Kitajima Y; Kozawa O
    Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):206-13. PubMed ID: 15583451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat.
    Iba T; Kidokoro A; Fukunaga M; Fuse S; Suda M; Kunitada S; Hara T
    Shock; 2002 Feb; 17(2):159-62. PubMed ID: 11837793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
    Tanaka M; Arai H; Liu N; Nogaki F; Nomura K; Kasuno K; Oida E; Kita T; Ono T
    Kidney Int; 2005 Jun; 67(6):2123-33. PubMed ID: 15882255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis.
    Nomura K; Liu N; Nagai K; Hasegawa T; Kobayashi I; Nogaki F; Tanaka M; Arai H; Fukatsu A; Kita T; Ono T
    Lab Invest; 2007 Feb; 87(2):150-60. PubMed ID: 17179958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
    Becker RC; Alexander JH; Li Y; Robertson T; Kunitada S; Spencer FA; Yang H; Harrington RA
    J Thromb Thrombolysis; 2004 Dec; 18(3):193-7. PubMed ID: 15815881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes.
    Kumura T; Hino M; Yamane T; Tominaga K; Tatsumi N
    Clin Chim Acta; 2000 Apr; 294(1-2):27-35. PubMed ID: 10727670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.